Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 26 of 27 for:    Echinacea

Topical Salve for Skin Oxygenation and Blood Flow (OHS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02394366
Recruitment Status : Completed
First Posted : March 20, 2015
Last Update Posted : November 8, 2018
Sponsor:
Information provided by (Responsible Party):
Ryan Bradley, National University of Natural Medicine

Brief Summary:
Delayed wound healing leads to increased risk for infection, and thus increased risk for morbidity and mortality. Skin oxygen delivery and peripheral blood flow predict wound healing. The investigators will conduct a double-masked, placebo-controlled cross-over clinical pilot trial in order to evaluate the effects of a topical, homeopathic/herbal salve (Original Healing Salve, Puremedy, Inc.) on skin oxygenation and peripheral blood flow.

Condition or disease Intervention/treatment Phase
Skin Oxygenation Peripheral Perfusion Other: Original Healing Salve (OHS) Other: OHS base only Phase 2

Detailed Description:
Delayed wound healing leads to increased risk for infection, and thus increased risk for morbidity and mortality. Skin oxygen delivery and peripheral blood flow predict wound healing. In order to evaluate the effects of a topical, homeopathic/herbal salve (Original Healing Salve, Puremedy, Inc.) on skin oxygenation and peripheral blood flow, the investigators will conduct a double-masked, placebo-controlled cross-over clinical pilot trial with randomized testing order to evaluate the effects of the salve on cutaneous oxygen saturation (TcPO2) and ankle-to-brachial pressure index (ABPI). The investigators will recruit thirty-two participants in two cohorts to participate, one with and one without type 2 diabetes, who are otherwise generally healthy without active wounds, ulcers or skin rashes. Both TcPO2 and ABPI will be measured before and after the application of both the homeopathic/herbal salve ("active"), and before and after the application of the inert salve base ("placebo"). Analyses will compare pre/post changes in TcPO2 and ABPI before and after application of the active salve within the same visit, and also compare the changes from the active salve to the before and after changes in TcPO2 and ABPI measured from the placebo salve. If the Original Healing Salve improves cutaneous oxygenation and/or ABPI, future research may evaluate the formula specifically for wound healing and antimicrobial effects. Thus the proposed research is a pilot study targeting mechanistic outcomes, which predict potential clinical efficacy. The proposed research is significant, as lower cost, more effective treatments are needed to improve wound healing and reduce the morbidity associated with the complications of delayed wound healing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Effects of Topical Herbal Salve on Cutaneous Oxygenation and Peripheral Blood Flow
Study Start Date : March 2015
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Arm Intervention/treatment
Experimental: Active
Original Healing Salve (Puremedy, Inc.) including 1x homeopathic dilutions of Calendula, Echinacea, and Sambucus extracts, plus extracts from pine and Balsam fir; acute effects only
Other: Original Healing Salve (OHS)
Topical salve (Puremedy, Inc.)

Placebo Comparator: Control
Original Health Salve olive oil and beeswax base only without homeopathic or herbal extracts; acute effects only
Other: OHS base only
Olive and beeswax salve base




Primary Outcome Measures :
  1. Transcutaneous oxygen pressure (TcPO2) [ Time Frame: 30 minutes ]
    Change in TcPO2 will be compared between 0 min and 30 mins between Active and Placebo arms


Secondary Outcome Measures :
  1. Ankle-to-Brachial Pressure Index (ABPI) [ Time Frame: 30 minutes ]
    Change in ABPI will be compared between 0 min and 30 mins between Active and Placebo arms


Other Outcome Measures:
  1. Trend in TcPO2 [ Time Frame: 0 to 30 minutes ]
    Longitudinal trend in TcPO2 will be evaluated via measurements taken at 5 minutes intervals over 30 minutes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have type 2 diabetes without known complications, i.e., eye damage (retinopathy), nerve damage (diabetic peripheral neuropathy), kidney damage (diabetic kidney disease), or heart damage (recent myocardial infarction or severe congestive heart failure)
  • Age ≥ 18 and ≤ 75
  • Willing and able to give informed consent
  • Able to follow protocol and attend visits
  • Able to read and write English

Exclusion Criteria:

  • Active malignancy, excluding basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix. If present, dermal cancers may not be located on or around the testing sites.
  • A recent cardiovascular event (e.g., myocardial infarction, stroke ≤ six months prior to screening visit), current coronary artery disease, angina, stage III or IV congestive heart failure, or stated history of coronary bypass surgery or heart stent placement.
  • Current active diabetic ulcers.
  • History of diabetic neuropathy.
  • Diagnosis of type 2 diabetes for longer than 10 years.
  • Diagnosis of type 1 diabetes.
  • Established diagnosis of peripheral artery disease (PAD) or intermittent claudication.
  • Established diagnosis of peripheral venous disease (PVD) or chronic venous insufficiency.
  • Active rash, wound, or ulcer on lower leg, including psoriasis or eczema.
  • Presence of edema > +1; pitting or non pitting.
  • Currently taking any of the following beta-blocker medications (due to potential impact on peripheral vasodilation): acebutolol (Sectral®), atenolol (Tenormin®), betaxolol (Kerlone®), bisoprolol fumarate (Zebeta®, Ziac®), carvedilol (Coreg®),metoprolol (Lopressor®, Toprol XL®), nadolol (Corgard®), nebivolol (Bystolic®), penbutolol (Levatol®), propranolol (Hemangeol®, Inderal LA® Inderal XL®, InnoPran XL®), esmolol (Brevibloc), sotalol (Betapace, Sorine), labetalol (Normodyne, Trandate), pindolol (Visken).
  • Currently taking any of the following cholinergic medications (due to potential impact on peripheral vasodilation): acetylcholine, atropine, bethanechol (Urecholine®), donepezil (Aricept®), ipratropium bromide (Atrovent®), neostigmine (Prostigmine®), nicotine (Nicoderm®, Nicotrol®), oxybutynin (Ditropan®), physostigmine, pilocarpine (Salagen®), pralidoxime (Protopam®), succinylcholine (Anectine®), tiotropium bromide (Spiriva®, Tiova®), tolterodine (Detrol®), vecuronium (Norcuron®).
  • Allergy to any ingredient found in the study products: pine resin, balsam fir resin, elder (Sambucus) flower and bark, marigold (Calendula), cone flower (Echinacea), olive oil, safflower oil or beeswax.
  • Walking Impairment Questionnaire Speed Scores between 0-18 due to risk for PAD (21).
  • Walking Impairment Questionnaire Distance Scores between 0-19 due to risk for PAD (21).
  • Presence of an unstable and/or significant medical disorder that would compromise the participant's safety to take part in the trial.
  • Use of tobacco products, e-cigarettes, nicotine patches and/or nicotine gum
  • Scleroderma
  • Raynaud's
  • Planned elective surgery within the next 6 weeks
  • Pregnant, nursing, or planning a pregnancy within the next 6 weeks

Publications:

Layout table for additonal information
Responsible Party: Ryan Bradley, Associate Professor, National University of Natural Medicine
ClinicalTrials.gov Identifier: NCT02394366     History of Changes
Other Study ID Numbers: 01202015
First Posted: March 20, 2015    Key Record Dates
Last Update Posted: November 8, 2018
Last Verified: November 2018

Keywords provided by Ryan Bradley, National University of Natural Medicine:
Skin oxygenation
peripheral perfusion